| LCP Disease | Legg-Calve-Perthes Disease ? Stages of LCP Disease(= Juvenile Idiopathic AVN) &nb... |
|---|---|
| RIND | Residual(= Reversible) Ischemic Neurologic Deficit |
| RV | 1) Residual Volume 2) Right Ventricle |
| FRC | Federal Radiation Council; frozen red cells; functional reserve capacity; functional residual capaci... |
| FRV | full-length retroviral [sequence]; functional residual volume |
| residual schizophrenia | Blunted or inappropriate affect, social withdrawal, eccentric behaviour, or loose associations, but without prominent psychotic symptoms, as the remains of former psychotic symptoms of schizophrenia. (05 Mar 2000) |
|---|---|
| residual urine | Urine remaining in the bladder at the end of micturition in cases of prostatic obstruction, bladder atony, etc. (05 Mar 2000) |
| residual volume | The volume of air remaining in the lungs at the end of a maximal expiration. Common abbreviation is rv. (12 Dec 1998) |
| neoplasm, residual | Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication) (12 Dec 1998) |
| functional residual air | The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc. (12 Dec 1998) |
| functional residual capacity | The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc. (12 Dec 1998) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |